TagsRheumatology 
Drinking Tea May Lower Disease Activity of Rheumatoid Arthritis

Rheumatoid arthritis (RA) is an autoimmune disorder caused by synovial inflammation of the joints, resulting in severe swelling and pain. Although the disease is incurable, previous studies have suggested that tea consumption may reduce the risk of ...

Aug 26, 2020
Golimumab Improves Sleep Problems and Pain in AS Patients

Adult patients with active ankylosing spondylitis (AS) treated with intravenously (IV) administered an anti-tumor necrosis factor (anti-TNF) monoclonal antibody, golimumab (GOL), demonstrated improvements in sleep problems, total back pain (TBP) and...

May 5, 2020
Risk of Serious Infections in Tofacitinib versus Other Biologic Drug Initiators in Patients with Rheumatoid Arthritis

Biologic or targeted synthetic disease modifying anti-rheumatic drugs (DMARDs) are well-known for increasing the risk of serious infections (SI). Few studies conducted in real-world setting directly compared the incidence rate (IR) of serious bacter...

Apr 22, 2020
Real Life 12Year Retention Rate of Subcutaneous Anti-TNF in Spondyloarthritis.Results from a Multicenter Cohort of 1170 Patients

Real Life 12 Year Retention Rate of Subcutaneous Anti-TNF in Spondyloarthritis. Results from a Multicenter Cohort of 1170 Patients By Dr. Andus Ng Spondyloarthritis (SpA) patients starting golimumab (GOL) have the best drug retention compared to tho...

Mar 30, 2020
A Way Out from the Vicious Cycle - Caring Mood Disorders in Systemic Lupus Erythematosus

The Complexity of NPSLE The definition of neuropsychiatric symptoms in SLE (NPSLE) is a tough challenge owing to the broad spectrum of neuropsychiatric (NP) symptoms that it encompasses, most of which are non-specific. In 1999, the American College ...

Mar 16, 2020
Treatment of Systemic Lupus Erythematosus: More than Disease Control

Treatment of Systemic Lupus Erythematosus: More than Disease Control Systemic lupus erythematous (SLE) is a complex, multisystem autoimmune disease with a heterogeneous range of clinical and immunological manifestations 1 . The development of diseas...

Mar 16, 2020
Treat-to-Target in Psoriatic Arthritis: What is New?

Psoriatic Arthritis (PsA) has been identified as a potentially destructive, disabling arthritis and affects women and men equally, with a prevalence of approximately 1 to 2 per 1000 in the general population 8 . Over the past few years, there has be...

Mar 16, 2020
Optimising Patient-reported Outcomes of Rheumatoid Arthritis Treatment with Janus-associated Kinase (JAK) Inhibitor

The Unmet Needs in RA Treatments Thanks to the development in therapeutics for RA in recent decades, better clinical remission can be achieved. However, the patient-reported pain, fatigue and disease activity level were not coincidental with the sev...

Mar 16, 2020
Risk Prediction and Preconception Counselling on Adverse Pregnancy Outcomes in Systemic Lupus Erythematosus

Risk Prediction and Preconception Counselling on Adverse Pregnancy Outcomes in Systemic Lupus Erythematosus Pregnancy is challenging for both women with systemic lupus erythematosus (SLE) and their treating physicians as it is associated with an inc...

Mar 16, 2020
International Conference of Chinese Rheumatologists (ICCR) 2019

International Conference of Chinese Rheumatologists (ICCR) 2019 The ICCR 2019 was successfully held on 30th November and 1 st December 2019. The ICCR is organised by the Hong Kong Society of Rheumatology (HKSR) and is one of the few occasions which ...

Dec 16, 2019